IMNM

SEC source: 0001415889-25-016979 · form4-06122025_080620.xml · derivative · entry 1

SWAIN SANDRA M · CIK 0001908755 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,864

Underlying: Common Stock · 18,864 shares

Expires 2035-06-09

F1 · derivative.exercise_date: The option vests in four quarterly installments, commencing from June 10, 2025 until the one-year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to the Reporting Person's continuous service with the Company on each respective vesting date.

SEC source: 0001415889-25-015478 · form4-06042025_010636.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,415

F1 · price: The weighted average purchase price for the transaction report was $9.38, and the range of prices were between $9.36 and $9.40, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-009201 · form4-03282025_090359.xml · derivative · entry 2

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 173,840

Underlying: Common Stock · 5,200 shares

Expires 2032-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-25-009201 · form4-03282025_090359.xml · nonDerivative · entry 1

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-25-009017 · form4-03262025_080357.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 806,736

F1 · price: The weighted average purchase price for the transaction report was $7.29, and the range of prices were between $7.16 and $7.40, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-009019 · form4-03262025_080315.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,415

F1 · price: The weighted average purchase price for the transaction report was $7.78, and the range of prices were between $7.37 and $8.51, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-008918 · form4-03252025_090350.xml · nonDerivative · entry 1

Tsai Philip · CIK 0002026600 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,300

SEC source: 0001415889-25-008920 · form4-03252025_090358.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,615

F1 · price: The weighted average purchase price for the transaction report was $8.21, and the range of prices were between $8.16 and $8.42, inclusive. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-25-002824 · form4-02042025_020240.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 669,636

F1 · kind: The Reporting Person purchased the shares in connection with the Issuer's recently completed underwritten public offering of common stock.

SEC source: 0001415889-24-027601 · form4-11252024_011157.xml · nonDerivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 519,636

F2 · price: The weighted average purchase price for the transaction report was $9.7787, and the range of prices were between $9.41 and $9.90. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-027601 · form4-11252024_011157.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 485,693

F1 · price: The weighted average purchase price for the transaction report was $9.5412, and the range of prices were between $9.41 and 9.68. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-027597 · form4-11252024_011120.xml · nonDerivative · entry 1

Tsai Philip · CIK 0002026600 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,000

F1 · price: The purchase price for the reported transactions was $9.43. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, the Reporting Person will provide the full information regarding the securities purchased.

SEC source: 0001415889-24-027599 · form4-11252024_011125.xml · nonDerivative · entry 1

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,805

F1 · price: The purchase price for the reported transactions was $9.478. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, the Reporting Person will provide the full information regarding the securities purchased.

SEC source: 0001415889-24-023809 · form4-09202024_110913.xml · derivative · entry 3

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,848

Underlying: Common Stock · 42,000 shares

Expires 2033-03-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Reporting Person's Form 3 filed on October 12, 2023 contains a scrivener's error reflecting an exercise price of $1.06 instead of the correct exercise price of $1.05.

F4 · derivative.exercise_date: 25% of the shares vested on March 24, 2023, and the remaining shares shall vest in 36 monthly installments thereafter.

SEC source: 0001415889-24-023809 · form4-09202024_110913.xml · nonDerivative · entry 2

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,476

F1 · kind: The shares were sold pursuant to sell to cover transactions.

F2 · price: The weighted average sale price for the transaction report was $16.01, and the range of prices were between $15.97 and $16.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-023809 · form4-09202024_110913.xml · nonDerivative · entry 1

Rosett Max · CIK 0001994071 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,856

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-021656 · form4-08202024_010805.xml · nonDerivative · entry 3

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,529

SEC source: 0001415889-24-021659 · form4-08202024_010811.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,615

F1 · price: The weighted average purchase price for the transaction report was $13.944, and the range of prices were between $13.750 and $14.210. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-021656 · form4-08202024_010805.xml · derivative · entry 4

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 179,040

Underlying: Common Stock · 19,524 shares

Expires 2032-06-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter.

SEC source: 0001415889-24-021656 · form4-08202024_010805.xml · nonDerivative · entry 2

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

F1 · kind: The shares were sold pursuant to sell to cover transactions.

F2 · price: The weighted average sale price for the transaction report was $13.925, and the range of prices were between $13.800 and $14.020. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-021656 · form4-08202024_010805.xml · nonDerivative · entry 1

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-24-021240 · form4-08132024_090811.xml · derivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 800,000

Underlying: Common Stock · 800,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-021230 · form4-08132024_090853.xml · derivative · entry 1

Rosett Max · CIK 0001994071 · EVP, Operations & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-021238 · form4-08132024_090806.xml · derivative · entry 1

Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Common Stock · 210,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-021236 · form4-08132024_090819.xml · derivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Common Stock · 130,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-021234 · form4-08132024_090830.xml · derivative · entry 1

Turner Bruce · CIK 0001993683 · Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 110,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-021226 · form4-08132024_090822.xml · derivative · entry 1

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Common Stock · 190,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-021228 · form4-08132024_090844.xml · derivative · entry 1

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-08-08

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-017531 · form4-06192024_010626.xml · derivative · entry 1

Tsai Philip · CIK 0002026600 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-06-16

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on June 17, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-017516 · form4-06192024_120629.xml · derivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-017526 · form4-06192024_010614.xml · derivative · entry 1

Boylan James P · CIK 0001953094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · shares: Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.

F2 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-017524 · form4-06192024_120638.xml · derivative · entry 1

SCHAFER CAROL · CIK 0001272181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-017522 · form4-06192024_120645.xml · derivative · entry 1

SWAIN SANDRA M · CIK 0001908755 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-017520 · form4-06192024_120643.xml · derivative · entry 1

WAGENHEIM PHILIP · CIK 0001405684 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-017518 · form4-06192024_120605.xml · derivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,333

Underlying: Common Stock · 11,333 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-013935 · form4-05212024_080525.xml · nonDerivative · entry 2

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 419,636

F2 · price: The weighted average purchase price for the transaction report was $13.7784, and the range of prices were between $13.62 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-014107 · form4-05222024_080525.xml · nonDerivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,615

SEC source: 0001415889-24-013935 · form4-05212024_080525.xml · nonDerivative · entry 1

SIEGALL CLAY B · CIK 0001167496 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,202

F1 · price: The weighted average purchase price for the transaction report was $13.907,and the range of prices were between $13.77 and $13.99. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.

SEC source: 0001415889-24-013577 · form4-05172024_090559.xml · derivative · entry 1

Rosett Max · CIK 0001994071 · EVP, Operations & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

Underlying: Common Stock · 30,000 shares

Expires 2034-05-15

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on May 16, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-011716 · form4-04302024_120419.xml · derivative · entry 1

SWAIN SANDRA M · CIK 0001908755 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,737

Underlying: Common Stock · 25,737 shares

Expires 2034-04-24

F1 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on April 25, 2024, and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001415889-24-004704 · form4-02222024_020242.xml · derivative · entry 1

Horn Kinney · CIK 0001831215 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2034-02-19

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on February 12, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-002121 · form4-02012024_010250.xml · derivative · entry 1

Rosett Max · CIK 0001994071 · EVP, OPERATIONS & INTERIM CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2034-01-30

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on January 31, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001415889-24-002119 · form4-02012024_010238.xml · derivative · entry 1

Stoneman Sandra G. · CIK 0001831144 · CHIEF LEGAL OFFICER & GC

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2034-01-30

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on January 31, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001209191-24-000861 · doc4.xml · derivative · entry 1

SCHAFER CAROL · CIK 0001272181 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,934

Underlying: Common Stock · 32,934 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on January 2, 2024 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001209191-23-058886 · doc4.xml · derivative · entry 1

Roberts Phil Noland · CIK 0002004455 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,000

Underlying: Common Stock · 275,000 shares

Expires 2033-12-12

F1 · derivative.exercise_date: 25% of the shares subject to the options vest on December 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

SEC source: 0001209191-23-057567 · doc4.xml · derivative · entry 1

Higgins Jack · CIK 0001993684 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-11-30

F1 · derivative.exercise_date: On December 1, 2023, Dr. Higgins was granted an option to purchase 200,000 shares of common stock. The option vests (i) with respect to 100,000 shares, 25% of such shares subject to the option, vest on November 17, 2024, and the remaining shares will vest monthly thereafter over three years, and (ii) with respect to the remaining 100,000 shares, which vesting shall commence as of the date a certain condition set forth in Dr. Higgins' Amended and Restated Offer Letter dated November 30, 2023, is satisfied, 25% of the shares subject to the option will vest 1 year from the completion of that certain condition, and the remaining shares will vest monthly thereafter over three years.

SEC source: 0001209191-23-054838 · doc4.xml · derivative · entry 1

BIENAIME JEAN JACQUES · CIK 0001221590 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,696

Underlying: Common Stock · 40,696 shares

Expires 2033-11-06

F1 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on November 7, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001209191-23-053984 · doc4.xml · derivative · entry 1

Barchas Isaac · CIK 0001808343 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,538

Underlying: Common Stock · 41,538 shares

Expires 2033-10-26

F1 · shares: Mr. Barchas waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Barchas' initial grant under the New NED Compensation Policy.

F2 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

SEC source: 0001209191-23-053983 · doc4.xml · derivative · entry 1

Boylan James P · CIK 0001953094 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,538

Underlying: Common Stock · 41,538 shares

Expires 2033-10-26

F1 · shares: Mr. Boylan waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Boylan's initial grant under the New NED Compensation Policy.

F2 · derivative.exercise_date: The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

F3 · balance_after: Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.

SEC source: 0001209191-23-053982 · doc4.xml · derivative · entry 1

Lechleider Robert · CIK 0001997584 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2033-10-26

F1 · derivative.exercise_date: 25% of the shares subject to the option vest on October 16, 2024, and the remaining shares will vest monthly thereafter over three years.